BRCA1 and neoplasm: Interestingly, not all cancers arising in BRCA1/2 mutation carriers are characterized by somatic inactivation of the remaining BRCA1/2 allele; therefore, it is advisable to supplement BRCA1/2 germ-line testing with the BRCA1/2 loss-of-heterozygosity (LOH) analysis of the tumor tissue [94,95].